Citadel Advisors’s Freeline Therapeutics Holdings plc American Depositary Shares FRLN Stock Holding History

Citadel Advisors’s Portfolio FRLN Stock Details FRLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-7,786	Closed	-$53.7K	–	15523
2023 Q1	$53.7K	Buy	7,786 +6,202	+392%	+$48.1K	﹤0.01%	12063
2022 Q4	$11.8K	Buy	+1,584	New	+$15.1K	﹤0.01%	13549
2021 Q3	–	Sell	-882	Closed	-$108K	–	14910
2021 Q2	$108K	Buy	+882	New	+$137K	﹤0.01%	12856
2020 Q4	–	Sell	-1,703	Closed	-$398K	–	11685
2020 Q3	$398K	Buy	+1,703	New	+$427K	﹤0.01%	7679

Other funds holding FRLN

Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

HCA

Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Citadel Advisors's FRLN Position: Q2 2023 in Review

Citadel Advisors sold out of Freeline Therapeutics Holdings plc American Depositary Shares (FRLN) in Q2 2023, closing a stake of 7,786 shares — an estimated $53.7K sold.

Citadel Advisors first reported a position in FRLN in Q3 2020 and held it in 4 quarters. The position peaked at $398K in Q3 2020. 11 funds tracked by Wall St. Rank hold FRLN as of Q2 2023.

Citadel Advisors reported no remaining Freeline Therapeutics Holdings plc American Depositary Shares position as of Q2 2023 after selling out during the quarter.
Citadel Advisors sold 7,786 Freeline Therapeutics Holdings plc American Depositary Shares shares in Q2 2023, an estimated $53.7K.
Citadel Advisors first reported a position in Freeline Therapeutics Holdings plc American Depositary Shares in Q3 2020 and held it in 4 quarters.
Citadel Advisors's Freeline Therapeutics Holdings plc American Depositary Shares position peaked at $398K in Q3 2020.
11 funds tracked by Wall St. Rank held Freeline Therapeutics Holdings plc American Depositary Shares as of Q2 2023.

Based on Citadel Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.